CPIX Cumberland Pharmaceuticals Inc

Price (delayed)

$1.63

Market cap

$23.13M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.59

Enterprise value

$26.23M

Cumberland Emerging Technologies, Inc.(www.cet-fund.com)is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, LaunchTN and WinHealth Pharma. The mission of CET is to bring biomedical technologies and products conceived at ...

Highlights
The gross margin has increased by 4.9% YoY
The quick ratio has increased by 10% QoQ but it has decreased by 8% YoY
Cumberland Pharmaceuticals's EPS has plunged by 111% YoY and by 34% from the previous quarter
The net income has shrunk by 111% YoY and by 34% QoQ

Key stats

What are the main financial stats of CPIX
Market
Shares outstanding
14.19M
Market cap
$23.13M
Enterprise value
$26.23M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.84
Price to sales (P/S)
0.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.68
Earnings
Revenue
$38.83M
EBIT
-$7.77M
EBITDA
-$1.82M
Free cash flow
$5.04M
Per share
EPS
-$0.59
Free cash flow per share
$0.36
Book value per share
$1.94
Revenue per share
$2.75
TBVPS
$4.19
Balance sheet
Total assets
$81.51M
Total liabilities
$54.32M
Debt
$21.65M
Equity
$27.49M
Working capital
$9.78M
Liquidity
Debt to equity
0.79
Current ratio
1.37
Quick ratio
1.1
Net debt/EBITDA
-1.71
Margins
EBITDA margin
-4.7%
Gross margin
83.5%
Net margin
-21.7%
Operating margin
-25.5%
Efficiency
Return on assets
-9.9%
Return on equity
-25.9%
Return on invested capital
-23.4%
Return on capital employed
-14.1%
Return on sales
-20%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CPIX stock price

How has the Cumberland Pharmaceuticals stock price performed over time
Intraday
2.52%
1 week
3.82%
1 month
1.88%
1 year
-6.86%
YTD
-9.02%
QTD
-2.98%

Financial performance

How have Cumberland Pharmaceuticals's revenue and profit performed over time
Revenue
$38.83M
Gross profit
$32.43M
Operating income
-$9.89M
Net income
-$8.42M
Gross margin
83.5%
Net margin
-21.7%
The company's net margin has shrunk by 117% YoY and by 36% QoQ
The net income has shrunk by 111% YoY and by 34% QoQ
The company's operating margin has shrunk by 72% YoY and by 5% QoQ
CPIX's operating income has dropped by 66% year-on-year and by 3.5% since the previous quarter

Growth

What is Cumberland Pharmaceuticals's growth rate over time

Valuation

What is Cumberland Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.84
P/S
0.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.68
Cumberland Pharmaceuticals's EPS has plunged by 111% YoY and by 34% from the previous quarter
CPIX's equity is down by 24% year-on-year and by 7% since the previous quarter
CPIX's P/B is 19% below its 5-year quarterly average of 1.0
The stock's price to sales (P/S) is 56% less than its 5-year quarterly average of 1.3 and 5% less than its last 4 quarters average of 0.6
The revenue has contracted by 3.1% YoY

Efficiency

How efficient is Cumberland Pharmaceuticals business performance
CPIX's return on invested capital has dropped by 149% year-on-year and by 42% since the previous quarter
Cumberland Pharmaceuticals's ROS has plunged by 144% YoY and by 42% from the previous quarter
The company's return on equity has shrunk by 144% YoY and by 43% QoQ
The ROA has plunged by 125% YoY and by 38% from the previous quarter

Dividends

What is CPIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CPIX.

Financial health

How did Cumberland Pharmaceuticals financials performed over time
The total assets is 50% greater than the total liabilities
The current ratio is down by 19% year-on-year but it is up by 7% since the previous quarter
The quick ratio has increased by 10% QoQ but it has decreased by 8% YoY
The company's debt is 21% lower than its equity
The debt to equity has grown by 39% YoY and by 27% from the previous quarter
CPIX's equity is down by 24% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.